Fig. 2: In vivo efficacy of DNM0547.
From: Computer-aided drug design to generate a unique antibiotic family
a DNM0547 activity against MRSA (ATCC 33591) in a rabbit ischemic ear model of infection. Control contained excipient cream only while DNM0547 was 2% (w/w) in excipient; control (n = 6) and DNM0547 (n = 10). Data are represented as mean ± SEM. Significance was determined using a two-way ANOVA with Geisser-Greenhouse correction with Šidák’s multiple comparisons test, P 0.05. b CFUs per gram of tissue were determined at the end of a rabbit ischemic ear model of infection; control (n = 4) and 2% DNM0547 (n = 7). Data are represented as individual data points with the line representing the mean and error as SEM. Significance was determine using a one-sided unpaired student’s t-test with Welch’s correction, ***P 0.008. c Mupirocin activity against MRSA (ATCC 33591) in a rabbit ischemic ear model of infection; control (n = 6) wounds and 2% mupirocin treated (n = 5). Data are represented as mean ± SEM. Significance was determined using a two-way ANOVA with Geisser-Greenhouse correction with Šidák’s multiple comparisons test. Differences between control and mupirocin treated animals were not statistically significant. d DNM0547 activity against MRSA (ATCC 33591) in a mouse cellulitis model of infection; control (n = 5) and 2% DNM0547 treated (n = 5). Data are represented as mean ± SEM. Significance was determined using a two-way ANOVA with Geisser-Greenhouse correction with Šidák’s multiple comparisons test, *P 0.05. e CFUs per gram of tissue were determined at the end of the mouse cellulitis model of infection; control (n = 5) and 2% DNM0547 treated (n = 5). Data are represented as individual data points with the line representing the mean. Significance was determine using a one-sided unpaired student’s t-test, ***P 0.0001.
